ClinicalTrials.gg
RecruitingNCT05587361Updated Apr 28, 2026

Beta-Adrenergic Modulation of Drug Cue Reactivity

A Phase 4 interventional study of Propranolol and Nicotine Patch in Tobacco Use Disorder, Nicotine Dependence and Cigarette Smoking, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by University of Oklahoma · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing Nicotine Patch in Tobacco Use Disorder — 4 open to participants now, 5 under way, 2 of them phase 3. Nicotine Patch · Tobacco Use Disorder.

Planned enrollment
30th of 42
80 · median 135
Started
2024
the only one that year
Phase 4
14 of 42
1 open now
Registered
40th of 42
by date

Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, this one is the 30th largest by planned enrollment, is the only one that started in 2024, is one of 14 in phase 4, and was the 40th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

4 of the 42 studies testing Nicotine Patch in Tobacco Use Disorder are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Nicotine Patch

Nicotine Patch: first FDA approval 1991 (NICODERM CQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing Nicotine Patch in Tobacco Use Disorder, or all of them as a file.
02

Study summary

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Read the detailed description

Cigarette use remains a serious public health problem in the United States and worldwide. Effective pharmacological interventions for smoking cessation exist, but these medications primarily target nicotine withdrawal and smoking reinforcement. The cues and contexts associated with smoking also play an important role in driving smoking behavior, but evidence is extremely mixed whether existing interventions can effectively attenuate smoking urges and behavior in response to these cues and contexts.

In a previous pilot trial, the investigators demonstrated that propranolol suppressed smoking cue reactivity and brain activation across a constellation of brain regions implicated in nicotine dependence. Here, the investigators seek to extend this work by examining effects when the drug is administered in combination with an established treatment targeting withdrawal and reinforcement (i.e., nicotine patch).

Following consent and screening/baseline activities, participants will attend four neuroimaging appointments each lasting approximately 5 hours. Participants will be fitted with a nicotine or placebo patch, fed a standard meal and then administered propranolol or placebo. Participants will complete questionnaires and have their heart rate/blood pressure monitored throughout the visit. During the MRI scan, participants will be asked to complete both resting scans and task-based scans during which participants will view images of smoking and non-smoking objects and scenes.

03

Conditions studied

  • Tobacco Use Disorder
  • Nicotine Dependence
  • Cigarette Smoking
04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Generally healthy
  2. Age 21-60
  3. Right-handed using a three-item scale
  4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC)
  5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months
  6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine >100 ng/ml
  7. Must identity at least 4 different smoking locations used in a typical week
  8. Able to read and understand English

Exclusion criteria

Exclusion Criteria:

  1. Inability to attend all required sessions
  2. Significant health problems that would preclude active participation
  3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)
  4. Current use of psychoactive medications/drugs as indicated by self-report or urine screen
  5. Positive breath alcohol concentration
  6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)
  7. Problems with vision that cannot be corrected with contacts or glasses
  8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)
  9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications
  10. Systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg (sitting or standing)
  11. Abnormal
  12. Presence of severe anemia
  13. Presence of electrolyte imbalance that could impact blood pressure
  14. Presence of any other for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Patch/Placebo Propranolol

    Placebo Nicotine Patch Placebo Propranolol

    Drug: Placebo Propranolol · Drug: Placebo Patch

  • Experimental
    Placebo Patch/Active Propranolol

    Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)

    Drug: Propranolol · Drug: Placebo Patch

  • Experimental
    Active Patch/Placebo Propranolol

    Active Nicotine Patch (14 mg) Placebo Propranolol

    Drug: Nicotine Patch · Drug: Placebo Propranolol

  • Experimental
    Active Patch/Active Propranolol

    Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)

    Drug: Propranolol · Drug: Nicotine Patch

Interventions

  • Propranolol Capsule; 40 mg IR

  • Nicotine Patch; 14 mg

  • DrugPlacebo Propranolol

    Placebo Capsule, no active ingredients

  • DrugPlacebo Patch

    Placebo Patch, no active ingredients

06

What researchers measure

Primary outcomes

  1. Cue-Provoked Craving Ratings

    Self-reported smoking urges in response to smoking and non-smoking cues during magnetic resonance imaging (MRI) scan. Scores range from 0 to 10 with higher values indicating increased craving for cigarettes.

    Time frame: Approximately 4-5 hours

  2. Blood-Oxygen Level Dependent (BOLD) Activation to Smoking Cues

    Blood-Oxygen Level Dependent (BOLD) Contrast (Smoking-Neutral) in Anterior Hippocampus, Amygdala, Dorsal Anterior Insula, Medial Prefrontal Cortex, Posterior Cingulate Cortex and Ventral Striatum

    Time frame: Approximately 4-5 hours

  3. Association between Smoking Urge and Brain Activation

    Indices of covariation between cue-provoked craving BOLD activation to smoking cues

    Time frame: Approximately 4-5 hours

  4. Hippocampus-Amygdala connectivity to smoking cues

    Index of connectivity between these brain regions

    Time frame: Approximately 4-5 hours

  5. Medial Prefrontal Cortex and Posterior Cingulate Cortex connectivity

    Index of connectivity between these brain regions

    Time frame: Approximately 4-5 hours

  6. Association between Smoking Urge and Brain Connectivity

    Indices of covariation between cue-provoked craving BOLD activation to smoking cues

    Time frame: Approximately 4-5 hours

07

Study locations

1 of 1 sites recruiting
  • Hardesty Center for Clinical Research and Neuroscience
    Tulsa, Oklahoma 74136, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 38 non-industry phase 4 interventional studies under Tobacco Use Disorder, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 28 months is below that.

Counting every sponsor, half of 38 studies reached it within 41 months; a quarter within 30 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 20, 2022
StartActual
Nov 26, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05587361
Collaborators
Oklahoma State University Center for Health Sciences, Duke University, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Nov 26, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Jason A Oliver, PhD
Contact
Jason-Oliver@ouhsc.edu
405-271-8001 ext. 14005
Isabel Brush, B.A.
Contact
Isabel-Brush@ouhsc.edu
Jason A Oliver, PhD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Propranolol · Nicotine Patch

Start the discussion